Stockreport

Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interi...

Sagimet Biosciences Inc. - Series A  (SGMT) 
PDF model and showed a significant improvement in liver fibrosis, while semaglutide alone did not significantly improve fibrosis Reductions of circulating lipids associate [Read more]